4-(6,7-dimethoxy-isochroman-1-ylmethyl)-morpholine | 70070-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 4-(6,7-dimethoxy-isochroman-1-ylmethyl)-morpholine
• 英文别名: dimethoxy-1-morpholinomethyl-isochromane；4-((3,4-Dihydro-6,7-dimethoxy-1H-2-benzopyran-1-yl)methyl)morpholine；4-[(6,7-dimethoxy-3,4-dihydro-1H-isochromen-1-yl)methyl]morpholine
• CAS: 70070-13-2
• 化学式: C₁₆H₂₃NO₄
• 分子量: 293.363
• InChiKey: WPLFNEXFRSUBLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  40.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-bromomethyl-6,7-dimethoxy-isochroman 、 吗啉 生成 4-(6,7-dimethoxy-isochroman-1-ylmethyl)-morpholine
  参考文献：
  名称：

  KUMAR A.; KHANNA J. M.; JAIN P. C.; ANAND N., INDIAN J. CHEM., 1978, B 16, NO 9, 793-796

  摘要：

  DOI：

文献信息

• Active substance combination for the treatment of diabetes
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1946778A1

  公开（公告）日：2008-07-23

  The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, used to treat diabetes, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，用于治疗糖尿病，包括该活性物质组合的药物、包括该活性物质组合的制药配方以及利用该活性物质组合制造药物的用途。
• Substituted pyrazoline for preventing weight gain
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1946777A1

  公开（公告）日：2008-07-23

  The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，该药物以体重增加作为副作用而知名，包括所述活性物质组合的药物、包括所述活性物质组合的药物制剂、以及利用所述活性物质组合制造药物。
• 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments
  申请人：TORRENS Antoni

  公开号：US20070073056A1

  公开（公告）日：2007-03-29

  The present invention relates to 4-substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及4-取代吡唑啉化合物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。
• DRUG OR COSMETIC
  申请人：Ishibashi, Michio

  公开号：EP1541174A1

  公开（公告）日：2005-06-15

  The present invention provides pharmaceuticals or cosmetics, which prevent sclerotic lesions causing apoptosis, degeneration, fibrosis and atrophy, and repair and regenerate the lesions selectively, comprising a compound which preferentially increases regeneration-promoting macrophages and a method for screening the compound which preferentially increases regeneration-promoting macrophages. Pharmaceuticals or cosmetics of the present invention are useful for renal lesions, pancreatic lesions and skin lesions, because these induce regeneration-promoting immunocompetent cells lesion-selectively against organ tissue disorders and cause repair and regeneration thereof. The present invention provides pharmaceuticals or cosmetics, which prevent sclerotic lesions causing apoptosis, degeneration, fibrosis and atrophy, and repair and regenerate the lesions selectively, comprising a compound which preferentially increases regeneration-promoting macrophages and a method for screening the compound which preferentially increases regeneration-promoting macrophages. Pharmaceuticals or cosmetics of the present invention are useful for renal lesions, pancreatic lesions and skin lesions, because these induce regeneration-promoting immunocompetent cells lesion-selectively against organ tissue disorders and cause repair and regeneration thereof.

  本发明提供了防止硬化性病变引起细胞凋亡、变性、纤维化和萎缩，并有选择地修复和再生病变的药物或化妆品，包括优先增加促进再生的巨噬细胞的化合物和筛选优先增加促进再生的巨噬细胞的化合物的方法。本发明的药物或化妆品可用于肾脏病变、胰腺病变和皮肤病变，因为这些药物或化妆品可针对器官组织病变有选择地诱导促进再生的免疫功能细胞，并使其修复和再生。 本发明提供了防止硬化性病变导致细胞凋亡、变性、纤维化和萎缩，并有选择性地修复和再生病变的药物或化妆品，其中包括优先增加促进再生的巨噬细胞的化合物和筛选优先增加促进再生的巨噬细胞的化合物的方法。本发明的药物或化妆品可用于肾脏病变、胰腺病变和皮肤病变，因为这些药物或化妆品可针对器官组织病变有选择地诱导促进再生的免疫机能细胞，并使其修复和再生。
• Method for screening for a substance for promoting regeneration of macrophages
  申请人：Ishibashi, Michio

  公开号：EP1950563A2

  公开（公告）日：2008-07-30

  The present invention provides a method for screening a compound that lesion-selectively induces regeneration-promoting immunocompetent cells inducing the immunoregulatory response of the repair and regeneration selectively on the lesion part.

  本发明提供了一种筛选化合物的方法，该化合物可在病变部位选择性地诱导促进再生的免疫功能细胞，诱导病变部位选择性地产生修复和再生的免疫调节反应。